Temisis
Company Details
Status: Private
Employees: 1-10
Location:
Vandœuvre-lès-Nancy, France
Type:
sample
Technology:
sample
About: “Temisis Therapeutics ("Temisis") is a pre-clinical stage biotechnology company developing innovative drugs derived from natural sources for the treatment of auto-immune and chronic inflammatory diseases, with an initial focus on psoriasis.
Temisis most advanced compound, TEM-1657, a first-in-class and orally bioavailable small molecule, has demonstrated highly promising preclinical efficacy and safety profile in animal model of psoriasis, superior to Apremilast (Otezla TM), a Standard of Care (SOC) for patients with mild to moderate plaque psoriasis. In addition, TEM-1657 exhibited strong protective effect against Ulcerative Colitis (UC) in rodent, a form of Inflammatory Bowel Disease (IBD), which indicates this compound has therapeutic potential for other autoimmune/inflammatory diseases. TEM-1657 and its analogues act through a novel and breakthrough mechanism of action (MoA) downmodulating the release of key proinflammatory cytokines.
Founded in December 2017, Temisis is based in Nancy and is a subsidiary of Plant Advanced Technologies ("PAT"), a plant-based biotechnology company specialized in the discovery and eco-friendly production of hard-to-source plant active extracts for the cosmetic, nutraceutical, agro-chemical and biotechnology markets.”
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Temisis | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.